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ABSTRACT 
This study was conducted to compare the anti-inflammatory efficacy of nanoencapsulated 
and free-form diclofenac in rat. Diclofenac-loaded liposomes were prepared using the 
proliposome method. The anti-inflammatory effects of nanoencapsulated and free diclofenac 
were evaluated using the carrageenan-induced paw edema, formalin-induced paw licking and 
cotton-pellet-induced granuloma tests in vivo. For carrageenan-induced paw edema, 2 and 20 
mg/kg liposome-encapsulated diclofenac showed significant paw volume reduction compared 
to free form diclofenac of equivalent dosage groups. In the formalin test, significant reduction 
in paw-licking time was observed in late phase for both liposome-encapsulated and free-form 
diclofenac (2 and 20 mg/kg) with the percentage of inhibition of 28.62, 60.17% for free-form 
diclofenac and 31.45, 78.84% for liposome-encapsulated diclofenac, respectively. In cotton-
pellet-induced granuloma test 20 mg/kg free-form diclofenac showed significant reduction in 
the size of granuloma in both transudative and granuloma weight with percentage of 
inhibition of 42.93 and 49.26%, respectively, when compared to controls. Interestingly, 20 
mg/kg nanoencapsulated diclofenac showed a larger reduction of the parameter with 
percentage of inhibition of 48.43 and 63.55%, respectively. Collectively, these results 
indicated that nanoencapsulated diclofenac exhibited statistically higher efficacy than free-
form diclofenac when orally administered. Hence, clinical dosage may be reduced thereby 
reducing the drug's adverse effects. 
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